Newly established GeneaMed company is working on a new, potentially crucial drug on lympholytic leukemia. It is going to be based on dendrimers – particles used as transporters for drugs in vivo. The key in its lifesaving abilities is chemical modification inducing death of carcinogenic cells. ...
Read more
On 1 November 2013, Genentech announced that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab) to be used with chlorambucil chemotherapy for the treatment of chronic lymphocytic leukemia (CLL). ...
Read more